Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gene expression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    897 result(s) found for: Gene expression. Displaying page 1 of 45.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-011097-15 Sponsor Protocol Number: OLA_ZIPRA Start Date*: 2009-08-25
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study.
    Medical condition: The study will be conducted in 42 healthy volunteers
    Disease:
    Population Age: Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007276-41 Sponsor Protocol Number: Ram_GEP_1 Start Date*: 2008-05-13
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Gene expression profiling in skeletal muscle of healthy subjects treated with ramipril
    Medical condition: healthy young males
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000126-38 Sponsor Protocol Number: OVG2012/05 Start Date*: 2014-04-08
    Sponsor Name:University of Oxford
    Full Title: Towards improved meningococcal vaccines: a randomised, descriptive, open label study exploring the relationship between gene expression signatures with reactogenicity and immunogenicity following v...
    Medical condition: This study aims to investigate gene expression following vaccination with 4CMenB and relate this to vaccine reactions and to immune response
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-002310-16 Sponsor Protocol Number: LHinPOR001 Start Date*: 2023-02-01
    Sponsor Name:UZ Brussel
    Full Title: Endometrial gene expression profiles during ovarian stimulation with recombinant human FSH with or without the addition of recombinant human LH in genuine poor responders.
    Medical condition: Infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006224-21 Sponsor Protocol Number: IJB-BCTL-20119167 Start Date*: 2013-06-20
    Sponsor Name:Jules Bordet Institute
    Full Title: A pre-operative window study evaluating Denosumab, a RANK-Ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer
    Medical condition: We have designed this study to investigate if denosumab can modulate a number of biological processes including prolferation, RANK signaling and the mammary stem cell subpopulation.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003768-31 Sponsor Protocol Number: NNF18OC0052256 Start Date*: 2019-12-05
    Sponsor Name:Lungemedicinsk Forskningsenhed
    Full Title: Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD.
    Medical condition: COPD and asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002165-34 Sponsor Protocol Number: RC19_0292 Start Date*: 2020-12-03
    Sponsor Name:CHU of Nantes
    Full Title: Predictive Signature of Benralizumab Response
    Medical condition: Severe asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003965-11 Sponsor Protocol Number: CC-TT-IMA-14 Start Date*: 2015-11-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: Targeted therapy with Imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period.
    Medical condition: colon cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000274-20 Sponsor Protocol Number: GNT-WAS-03 Start Date*: 2014-05-14
    Sponsor Name:Genethon
    Full Title: LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08)
    Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopeni...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10047992 Wiskott-Aldrich syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001648-12 Sponsor Protocol Number: OVG2015/02 Start Date*: 2015-09-03
    Sponsor Name:University of Oxford
    Full Title: A phase II, open label trial to describe immune and transcriptional responses to MF59 adjuvanted trivalent influenza vaccine (ATIV) in 13-24 month healthy children and adults 18-65 years
    Medical condition: This trial is investigating healthy children and adult's gene expression and immune response to the Fluad (MF59)-adjuvanted trivalent influenza vaccine and also comparing these to the local and gen...
    Disease:
    Population Age: Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004573-32 Sponsor Protocol Number: 21-05 Start Date*: 2021-10-05
    Sponsor Name:Centre Hospitalier Annecy Genevois
    Full Title: Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) versus Standard-Dose (QIV-SD), in subjects 65 years of age and older on innate immunity, including gene expression.
    Medical condition: Healthy volunteers (influenza vaccination)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002069-30 Sponsor Protocol Number: 13069 Start Date*: 2008-12-05
    Sponsor Name:Bayer Vital GmbH
    Full Title: A randomized, double-blind, single centre, placebo-controlled pilot study to assess on a molecular level the influence of a 5 % dexpanthenol ointment in subjects with previously injured skin by inv...
    Medical condition: Biopsy wounds on healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001681-25 Sponsor Protocol Number: 23681 Start Date*: 2015-07-15
    Sponsor Name:Merck KGaA
    Full Title: An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Ex...
    Medical condition: Small for Gestational Age
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-000644-13 Sponsor Protocol Number: N08AFT Start Date*: 2008-07-10
    Sponsor Name:NKI-AVL
    Full Title: A randomized, prospective trial of 2-6 weeks pre-operative hormonal treatment for hormone receptor positive breast cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - response in molecular ...
    Medical condition: Invasive Breast Cancer, tumor size >= 1 cm (NOT inflammatory breast cancer), no clues of metastatic disease, no multicentric breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000677-23 Sponsor Protocol Number: CLCL161A2201 Start Date*: 2012-10-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) IT (Completed) BE (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002364-13 Sponsor Protocol Number: M16VIB Start Date*: 2018-01-23
    Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital (NKI-AVL)
    Full Title: MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer
    Medical condition: colon carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002106-48 Sponsor Protocol Number: BCF-2009.01 Start Date*: 2012-07-06
    Sponsor Name:University College Dublin
    Full Title: An Investigative Study to characterize gene expression patterns in myeloid cells that are triggered during acute asthma exacerbations, and to identify associated genes/gene networks that are Omaliz...
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003938-41 Sponsor Protocol Number: IMP 28364 Start Date*: 2007-09-25
    Sponsor Name:Merck Lipha Santé SAS
    Full Title: Open label pilot study on gene expression profiling of the endometrial tissue in patients undergoing Assisted Reproductive Technology (ART: only IVF) with GONAL-f.
    Medical condition: This study will be conducted in infertile women justifying ART (Assisted Reproductive Technology) treatment (only IVF - In Vitro Fecondation)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056204 In vitro fertilisation LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000925-38 Sponsor Protocol Number: UCL13/0076 Start Date*: 2017-01-04
    Sponsor Name:University College London (UCL)
    Full Title: GO-8: Gene therapy for haemophilia A using a novel serotype 8 capsid pseudotyped adeno-associated viral vector encoding Factor VIII-V3
    Medical condition: Severe Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-000298-11 Sponsor Protocol Number: ISS22810078 Start Date*: 2015-09-02
    Sponsor Name:AZIENDA OSPEDALIERA "ISTITUTI OSPITALIERI" DI CREMONA
    Full Title: A phase II, open label, controlled study of olaparib in locally advanced ER, PgR and HER2 negative (Triple Negative) and in locally advanced germline BRCA mutation-positive breast cancer patients: ...
    Medical condition: Locally advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 08:06:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA